{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T03:59:11Z","timestamp":1754193551969,"version":"3.41.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04796-3","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:33:01Z","timestamp":1751869981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma"],"prefix":"10.1007","volume":"95","author":[{"given":"Wenpeng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"4796_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G et al (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2011\u20132015. Neuro Oncol 20:iv1\u2013iv86. https:\/\/doi.org\/10.1093\/neuonc\/noy131","journal-title":"Neuro Oncol"},{"key":"4796_CR2","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013227. https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"4796_CR3","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/jco.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L et al (2022) Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients age 60 years and younger: Long-Term results of the randomized phase II PRECIS study. J Clin Oncol 40:3692\u20133698. https:\/\/doi.org\/10.1200\/jco.22.00491","journal-title":"J Clin Oncol"},{"key":"4796_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"key":"4796_CR5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/bcp.15134","volume":"88","author":"Z Song","year":"2022","unstructured":"Song Z, Hu Y, Liu S et al (2022) Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological society. Br J Clin Pharmacol 88:2456\u20132472. https:\/\/doi.org\/10.1111\/bcp.15134","journal-title":"Br J Clin Pharmacol"},{"key":"4796_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","volume":"17","author":"S Bezabeh","year":"2012","unstructured":"Bezabeh S, Mackey AC, Kluetz P et al (2012) Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 17:550\u2013554. https:\/\/doi.org\/10.1634\/theoncologist.2011-0431","journal-title":"Oncologist"},{"key":"4796_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/ckj\/sfu093","volume":"7","author":"NJ Connors","year":"2014","unstructured":"Connors NJ, Sise ME, Nelson LS et al (2014) Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase. Clin Kidney J 7:590\u2013592. https:\/\/doi.org\/10.1093\/ckj\/sfu093","journal-title":"Clin Kidney J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04796-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04796-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04796-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:33:02Z","timestamp":1751869982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04796-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4796"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04796-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Medical Ethics Expert Committee of Zibo Central Hospital (2025 Research No. 044). All participants were informed about the study protocol and provided written informed consent to participate in the study. I confirm that all methods were performed in accordance with the relevant guidelines. All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"71"}}